mRNA DISPLAY ANTIBODY LIBRARY AND METHOD
Patent Information
- Application Number
- JP2024150043
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-01-31
AI Technical Summary
【0027】 本発明の主題の様々な目的、特徴、態様及び利点は、添付の図面とともに、好ましい実施形態の以下の詳細な説明からより明らかになるであろう。
Smart Images

Figure 2024167352000001_ABST
Abstract
Description
[Technical field]
[0001] The field of the invention is compositions and methods for extremely high diversity antibody libraries, particularly as it relates to mRNA display libraries and the use of mRNA display libraries to generate recombinant high affinity binders. [Background technology]
[0002] The background discussion includes information that may be useful in understanding the present invention. No admission is made that any of the information provided herein is prior art or relevant to the invention(s) claimed herein, or that any publication referenced specifically or implicitly is prior art.
[0003] All publications and patent applications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. In the event that the definition and use of a term in an incorporated reference is inconsistent with or contradicts the definition of that term provided herein, the definition of that term provided herein shall apply and the definition of that term in the reference shall not apply.
[0004] Targeting tumor antigens or neoepitopes with high affinity, specific antibodies or binding molecules has been proven to be an effective method for treating cancer patients. As more and more patient-specific and / or cancer-specific tumor antigens and / or neoepitopes are identified in vivo, in vitro, or in silico through omics data analysis, there is an increasing demand to create antibody or display libraries that can select stable, soluble, functional, and adaptable antibodies or binders with a high probability. Although high affinity specific antibodies or binding molecules can be identified in or derived from natural antibody pools, such identified or derived natural antibodies or binders may not be effective or specific because the diversity of such natural antibodies may be limited depending on the frequency or intensity of exposure to such antigens or neoepitopes.
[0005] As one approach to solving such problems, recombinant phage display libraries can be used. Such approaches allow the creation of libraries with reasonably high diversity, but often require multiple enrichment procedures for binders, which is laborious and time-consuming. Moreover, despite the relatively large diversity, binders tend to lack ideal affinity and stability. Furthermore, diversity is usually limited by practical considerations such as library amount, transfection efficiency, etc. Such approaches and others can be further optimized using multiple artificial selection pressures, for example, as described in WO 2006 / 072773. Such methods may improve stability characteristics, but require significant amounts of library manipulation and time.
[0006] In yet another approach, mRNA display can be performed. Here, mRNA sequences encoding candidate binding molecules (typically scFvs) are linked to a puromycin molecule at their 3' end, and peptides encoded by the mRNA sequences are generated via in vitro translation to generate fusion products directly linking the mRNA to the protein encoded by the mRNA. However, while current mRNA display technology advantageously avoids problems associated with transfection limitations and allows, at least conceptually, higher diversity, problems of structural integrity or stability, relatively low affinity, and / or cross-reactivity still remain. To further improve at least selected binding properties of scFvs from mRNA display, VH-CDR3 spectratyping analysis has been performed (see Protein Engineering, Design & Selection, 2015, vol.28 no.10, pp.427-435). However, such a process requires iterative analysis and may not be productive for all antigens.
[0007] Thus, while methods for generating and identifying candidate binders using mRNA display and other methods are known, highly diverse libraries of binders with high structural integrity / stability, low affinity, and / or low cross-reactivity have remained elusive. Thus, there remains a need for improved compositions, methods, and uses of mRNA display libraries for the rapid generation of stable recombinant high affinity binders. Summary of the Invention [Means for solving the problem]
[0008] The present subject matter is directed to various compositions, methods, and uses of high diversity nucleic acid libraries encoding multiple antibodies or antibody fragments that enable reliable and efficient identification of stable, soluble, functional antibodies or binders to a variety of biomolecules, particularly cancer antigens or neoepitopes. Accordingly, one aspect of the subject matter includes a method of making a high diversity nucleic acid library encoding multiple antibodies or antibody fragments. The method includes creating three sub-libraries, each having multiple members: (1) V H -CDR1 / 2 sublibrary, (2) multiple V H -CDR3 sublibrary, and (3) V L Sub-libraries are generated or provided. Each member of the three sub-libraries contains at least one random cassette with a plurality of degenerate base positions. At least a portion of the members of at least two of the three libraries are recombined to form an expression library member in an expression library, which has a plurality of expression library members. Each expression library member encodes a separate antibody or antibody fragment. In a preferred embodiment, the expression library members are transcribed into mRNA fragments, which are then conjugated at their 3' ends with a puromycin molecule.
[0009] In another aspect of the inventive subject matter, the inventors contemplate a composition having a plurality of nucleic acid libraries. The plurality of nucleic acid libraries comprises: (1) a nucleic acid library having a plurality of nucleic acid libraries each ...; H -CDR1 / 2 sublibrary, (2) multiple V H -CDR3 sublibrary, and (3) V L Each of the sub-libraries (1) to (3) includes a plurality of members, and each member of the sub-library includes at least one random cassette having a plurality of degenerate base positions.
[0010] In yet another aspect of the inventive subject matter, we contemplate the use of the above compositions to generate highly diverse nucleic acid libraries.
[0011] In yet another aspect of the inventive subject matter, the inventors contemplate a high diversity nucleic acid library composition having a plurality of nucleic acid library members. The high diversity nucleic acid library members include recombinant nucleic acids that include a plurality of random cassettes, each having a plurality of degenerate base positions. The plurality of random cassettes includes: (1) V H -CDR1 / 2 sublibrary, (2) multiple V H -CDR3 sublibrary, and (3) V L From the sub-libraries, at least two members are derived from either of the two libraries.
[0012] In yet another aspect of the inventive subject matter, the inventors contemplate the use of a high diversity nucleic acid library to generate therapeutic recombinant antibodies against cancer neoepitopes.
[0013] In yet another aspect of the subject matter, we contemplate a method for producing a recombinant antibody, comprising generating three sub-libraries, each having a plurality of members: (1) V H -CDR1 / 2 sublibrary, (2) multiple V H -CDR3 sublibrary, and (3) V L Sub-libraries are created or provided. Each member of the three sub-libraries contains at least one random cassette having a plurality of degenerate base positions. At least a portion of the members of at least two of the three libraries are recombined to form an expression library member in an expression library, which has a plurality of expression library members. Each expression library member encodes a separate antibody or antibody fragment. The method then continues with the production of a recombinant antibody or fragment thereof using the expression library members.
[0014] In yet another aspect of the inventive subject matter, the inventors contemplate a method for isolating high affinity binders having an affinity of 100 nM or less for an antigen by contacting the antigen with a composition constructed by the above method.
[0015] In yet another aspect of the inventive subject matter, the inventors contemplate a recombinant nucleic acid fragment generated using an oligonucleotide selected from Table 1 or Table 2 provided below.
[0016] In yet another aspect of the inventive subject matter, we contemplate a synthetic nucleic acid mixture having a nucleic acid sequence selected from Table 1 or Table 2 provided below.
[0017] In yet another aspect of the inventive subject matter, we contemplate a recombinant virus that includes a recombinant nucleic acid that includes members of an expression library that encode distinct antibodies or antibody fragments. The members of the expression library include: (1) V H -CDR1 / 2 sublibrary, (2) multiple V H -CDR3 sublibrary, and (3) V L creating or providing sub-libraries, each of which contains a plurality of members, each member of which contains at least one random cassette having a plurality of degenerate base positions; H -CDR1 / 2 sublibraries, multiple V H -CDR3 sublibraries, and V L The expression library is generated by recombining at least a portion of at least two members of the sub-libraries to form an expression library member in the expression library.
[0018] Typically, the recombinant virus is a genetically modified, hypoimmunogenic virus, which may most preferably be a human adenovirus serotype 5 having a mutation in at least one of the following genes: E1A, E1B, E2B, E3.
[0019] In some embodiments, V H - a plurality of members of the CDR1 / 2 sublibrary are H Part of CDR1 and V HIn such an embodiment, the V H - a plurality of members of the CDR1 / 2 sublibrary are H In another embodiment, the V H - a plurality of members of the CDR1 / 2 sublibrary are H At least a portion of CDR1 and V H It contains multiple random cassettes corresponding to a portion of CDR2.
[0020] In some embodiments, V H - a plurality of members of the CDR3 sublibrary are selected from the group consisting of V H Contains a random cassette corresponding to at least a portion of CDR3. H It is contemplated that at least two random cassettes of the members of the -CDR3 sublibrary encode peptides of different lengths. L Multiple members of a sublibrary can be L A part of CDR3 contains a random cassette.
[0021] Typically, the recombination step comprises H - at least a portion of the members of the CDR1 / 2 sublibrary and a plurality of V H -CDR3 sublibraries and fused together to produce V H V in the domain library H forming a domain library member, H The domain library contains multiple V H In such an embodiment, the members of the expression library include a domain library member, such as a V L Isolating at least a portion of the members of the sublibrary and L Some of the members of the sublibrary and V HIt is contemplated that the expression library member is generated by fusing one of the V domain library members to one of the V domain library members to form an expression library member. H - at least a portion of the members of the CDR1 / 2 sublibrary and a plurality of V H - one of the CDR3 sub-libraries and fusing them together to form the first group of expression library members.
[0022] Optionally, the recombinant nucleic acid can further comprise a nucleic acid fragment encoding a signaling peptide that facilitates secretion of a separate antibody or antibody fragment.
[0023] In yet another aspect of the inventive subject matter, we contemplate a method for producing a recombinant antibody, comprising: (1) a V H -CDR1 / 2 sublibrary, (2) multiple V H -CDR3 sublibrary, and (3) V L Sub-libraries (each of these sub-libraries (1) to (3) includes a plurality of members) are generated or provided. Most preferably, each member of the sub-library includes at least one random cassette having a plurality of degenerate base positions. The method then includes: H -CDR1 / 2 sublibraries, multiple V H -CDR3 sublibraries, and V L This is followed by recombining at least a portion of at least two members of the sub-libraries to form an expression library member in an expression library, the expression library comprising a plurality of expression library members, each expression library member encoding a separate antibody or antibody fragment. A recombinant viral vector can then be generated that comprises at least one expression library member.
[0024] Typically, the recombinant virus is a genetically modified, hypoimmunogenic virus, which may most preferably be a human adenovirus serotype 5 having a mutation in at least one of the following genes: E1A, E1B, E2B, E3.
[0025] In some embodiments, the random cassette is generated using oligonucleotides selected from SEQ ID NO: 1 through SEQ ID NO: 25. Optionally, the recombinant viral vector further comprises a nucleic acid fragment encoding a signaling peptide that facilitates secretion of a distinct antibody or antibody fragment.
[0026] Preferably, the method may further comprise contacting a recombinant virus carrying the recombinant viral vector with a mammalian cell. In some embodiments, the contacting comprises administering the recombinant virus to a mammal. In other embodiments, the mammalian cell is an autologous cell of a patient with a tumor, and the contacting comprises co-incubating the autologous cell with the mammalian cell ex vivo.
[0027] Various objects, features, aspects and advantages of the present subject matter will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawings. [Brief description of the drawings]
[0028] [Figure 1] One exemplary randomization strategy using the VH3 / Vk1 pair is shown. [Diagram 2] 1 shows exemplary positions for sequence randomization in heavy chain CDR1 and CDR2. [Diagram 3] 1 shows an exemplary sequence randomization in heavy chain CDR3. [Figure 4] An exemplary sequence randomization in the light chain CDR3 is shown with the nucleic acid sequence on the left and amino acid selection on the right. [Diagram 5] 1 shows an exemplary generation of hybrid nucleic acid elements by isolating and combining random cassettes of multiple recombinant nucleic acid segments. [Figure 6] FIG. 1 shows the results of size exclusion chromatography showing a single peak indicating stable protein expression of αB7-H4801. [Figure 7] Capillary electrophoresis sodium dodecyl sulfate (CE-SDS) data showing similar molecular behavior of αB7-H4801 compared to commercial antibodies. [Figure 8] 1 shows a graph depicting binding of in vitro selected αB7-H4 antibodies to B7-H4. [Figure 9] Figure 1 shows a graph of the functional analysis of in vitro selected αB7-H4 and αPD-L1 binders. [Figure 10] 1 shows a graph depicting the binding affinity of αB7-H4 scFv and αB7-H4 IgG1. [Figure 11] IL-8 activity assay by measuring the change in neutrophil size and the results thereof. [Figure 12] 1 shows a bar graph illustrating the neutralizing effect of αIL-8 antibodies on IL-8 activity to increase neutrophil size. [Figure 13] 1 shows an IL-8 activity assay and the results shown in a bar graph demonstrating the neutralizing effect of αIL-8 antibodies on IL-8 antibody activity by inhibiting neutrophil migration. [Figure 14] 1 shows exemplary results using the mRNA display library compositions presented herein with selected antigen targets. [Figure 15] Binders were identified using the mRNA display library compositions presented herein, and an exemplary graph showing the affinity of selected binders configured as scFv versus IgG is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] The inventors have now discovered that specific and effective recombinant antibodies or fragments thereof can be generated or identified by constructing a high diversity nucleic acid library with targeted diversity of selected domains of antibodies or fragments thereof encoded by members of the high diversity nucleic acid library. To achieve such a goal, the inventors have now discovered that one or more domains or subdomains of the antibodies / binders can be preselected and multiple nucleic acid sub-libraries can be generated using random cassettes within the preselected domains or sub-domains. The inventors have further discovered that members of the sub-libraries can be recombined to construct a high diversity nucleic acid library that allows high diversity among the members of the library while increasing the probability of identifying antibodies / binders that are stable, soluble, functional and adaptable when used in vivo against cancer antigens or neoepitopes (preferably cancer-specific, patient-specific neoepitopes or neoantigens).
[0030] Indeed, as shown in more detail below, the libraries presented herein typically have binders with K values of 100 nM or less, more typically 10 nM or less, in a single or two-pass enrichment. d Further, the contemplated system and method allows for the isolation of at least one binder for any antigen having at least 10 9 , at least 10 10 , at least 10 11 , at least 10 12 , at least 10 13 , at least 10 14 , at least 10 15 , or at least 10 16 It should be appreciated that this approach allows for the construction of scFv libraries with a diversity of different library members in a significantly reduced time frame compared to traditional library construction, thus substantially increasing the rate of antibody discovery.
[0031] As used herein, the term "tumor" refers to, and is used interchangeably with, one or more cancer cells, cancer tissues, malignant tumor cells, or malignant tumor tissues that may be located or found in one or more anatomical locations within the human body.
[0032] As used herein, the term "bind" refers to, and can be used interchangeably with, the terms "recognize" and / or "detect," and the interaction between two molecules is greater than or equal to 10 -6 M or less or 10 -7 K below M D It has high affinity.
[0033] As used herein, the term "provide" or "providing" refers to and includes any of the acts of manufacturing, making, arranging, making available, or preparing for use.
[0034] Construction of nucleic acid sublibraries In general, the structural components of an antibody (heavy chain, light chain, constant domain, variable domain) are closely related to their functions. For example, the variable domain (V H ) and light chain (V L ) together constitute the epitope binding domain that confers specificity to the antibody. H and V L Each of the V antigens contains three complementarity determining regions (CDRs, CDR1-3) with unique amino acid sequences based on their specificity for antigens. H and V L It has previously been contemplated that a recombinant nucleic acid library for generating or identifying antibodies could be generated by randomizing the sequences encoding the CDRs of V. H and V L While completely randomizing all CDRs of V could potentially bring great diversity to the library, H and V LWe have found that generating all combinations of random sequences and screening all randomized combinations also creates inefficiencies because not all of the possible library members can be soluble or stably expressed when recombined to form an antibody (e.g., IgG1, etc.). Furthermore, covering the entire diversity space is not practical due to the sheer number of possible library members.
[0035] Therefore, we have H and V L The subdomains of different antibodies (or the genes encoding them) are divided into two categories: H Or V L It is contemplated that the V may be divided into framework regions that are generally common between the V and VFv, as well as targeted diversification regions that may be at least partially or completely randomized without significantly affecting the stability and / or solubility of the final peptide product (e.g., scFv, IgG1, etc.). H The targeted diversification region of V comprises at least a portion of CDR1, CDR2-n (the N-terminal side of CDR2), CDR2-c (the C-terminal side of CDR2), and CDR3. L The targeted diversification region comprises at least a portion of the CDR3.
[0036] Thus, in one exemplary and particularly preferred embodiment of the present subject matter, the nucleic acid library comprises V H and / or V LThe present invention can be produced by generating recombinant nucleic acids comprising one or more random sequence cassettes in one or more targeted diversification regions of the target diversification region. In one preferred embodiment, the inventors contemplate three different sub-libraries with different sets of random sequence cassettes in different targeted diversification regions, such that each sub-library preserves the diversity within the randomized targeted diversification region, while avoiding having too many randomized recombinant sequences in a single sub-library, which may make the amount of a single sub-library impractical or inefficient to handle for rapid or timely screening. Furthermore, the conserved regions between the targeted diversification regions are selected or designed for maximum stability and solubility.
[0037] In one embodiment, the sub-library is H - Includes a CDR1 / 2 sub-library. V H -CDR1 / 2 sublibrary is V H At least a portion of CDR1 and / or V H As used herein, V includes a plurality of recombinant nucleic acids (e.g., recombinant DNA) having one or more random sequence cassettes corresponding to a portion of CDR2. H A random cassette corresponding to a portion of CDR1 means that the random cassette is located within a region of the recombinant nucleic acid, in which the sequence encoding the CDR1 portion is the V H V domain that is at least structurally or functionally similar to H It should be present to code for part of the domain. For example, V H - The recombined nucleic acids in the CDR1 / 2 sub-library have the following structure (randomized regions are underlined, fixed sequenced regions are in brackets): [ka] As used herein, UTR refers to untranslated region, and FW refers to framework region (e.g., FW1 is a first framework region that can be different from the second framework region (FW2)). In this structure, random sequence cassettes can be inserted in CDR1 or CDR2, or preferably in both CDR1 and CDR2 regions. In some embodiments, two or more random sequence cassettes, preferably two random sequence cassettes, can be inserted in the region of CDR2: CDR2-n (for the 5'-end side of CDR2) and CDR-c (for the 3'-end side of CDR2).
[0038] The sublibraries also support multiple V H -CDR3 sub-libraries. H - each of the CDR3 sub-libraries is H The invention includes a plurality of recombinant nucleic acids (eg, recombinant DNA) having one or more random sequence cassettes corresponding to at least a portion of the CDR3. V H - As with the CDR1 / 2 sublibrary, V H - The recombined nucleic acids in the CDR1 / 2 sub-library may have the following structure (randomized regions are underlined, fixed sequenced regions are in brackets): [ka] Preferably, V H -CDR1 / 2 sublibrary and / or V H The fixed sequences of the recombinant nucleic acids of the -CDR3 sublibraries (e.g., promoter-5'UTR-FW1+CDR1+FW2+CDR2+FW3, FW4) are selected to use the most common and / or conserved sequences in natural antibodies (e.g., IgG1 against various antigens) so that the fixed sequences are the most expressible and adaptable to multiple formats, including single chain variable fragments (scFv), modified forms of scFv, full length immunoglobulins, or peptides expressed as part of immunoglobulins. Thus, in a preferred embodiment, V H- Recombinant nucleic acids of the CDR1 / 2 sublibrary and V H - The fixed sequences of the recombined nucleic acids of the CDR3 sub-libraries are at least 70%, preferably at least 80%, more preferably at least 90% identical (shared) with each other.
[0039] The sublibraries are also L It may contain sub-libraries. L The sub-library is V L A plurality of recombinant nucleic acids (e.g., recombinant DNA) having one or more random sequence cassettes corresponding to at least a portion of the CDR3. H - As with the CDR1 / 2 sublibrary, V H - The recombined nucleic acids in the CDR1 / 2 sub-library may have the following structure (randomized regions are underlined, fixed sequenced regions are in brackets): [ka] Preferably, V L The fixed sequences of the recombinant nucleic acids of the sub-library are V H -CDR1 / 2 sublibrary or V H - at least 70%, preferably at least 80%, more preferably at least 90% identical (shared) with those of the recombined nucleic acids of the CDR3 sub-library.
[0040] While any randomized sequence can be considered for creating the random sequence cassette, the present inventors have H CDR1, CDR2, CDR3 and V L It is contemplated that strategic random sequence cassettes for the CDR3 of a domain will confer high complexity and a large potential binding surface when expressed as a binding peptide (eg, scFv, etc.). For example, V HThe strategic random sequence cassette for CDR1, CDR2 of the CDR1 / 2 sub-library may be a semi-random sequence cassette having 3 or less, preferably 2 or less, or more preferably 1 random sequence per cassette (encoding 3 or less, 2 or less, or 1 random amino acid per cassette). The position of the random sequence in the random cassette may vary depending on the random amino acid in the cassette. In another example, V H The strategic random sequence cassette for the CDR3 of the CDR3 sublibrary may contain more randomized sequences such that there are 4 or more, preferably 5 or more, or more preferably 6 or more random sequences per cassette (encoding 4 or more, preferably 5 or more, or more preferably 6 or more random amino acids per cassette). L The strategic random sequences for the CDR3 of the sub-library may include more randomized sequences such that there are 4 or more, preferably 5 or more, or more preferably 6 or more random sequences per cassette (encoding 4 or more, preferably 5 or more, or more preferably 6 or more random amino acids per cassette).
[0041] In certain preferred embodiments of the present subject matter, the inventors have determined that the preferred random sequence cassettes for the sub-libraries are those set forth in Table 1 (V H -CDR1 / 2 sublibraries and V H -CDR3 sublibrary), and Table 2 (V LIt is contemplated that the CDR1 random sequence cassettes may be generated using the oligonucleotides presented in Table 1 and Table 2 (for the sub-libraries). As shown in Tables 1 and 2, each oligonucleotide contains a random sequence (highlighted) with a degenerate code shown as an IUPAC ambiguity code. For example, one oligonucleotide for the CDR1 random sequence cassette contains the random sequence "RVT", which represents "A / G, A / C / G, T", the combination of which can code for one of threonine (T), alanine (A), asparagine (N), aspartic acid (D), serine (S), or glycine (G). The amino acid choices coded for by the degenerate codons are presented to the right and are indicated with an X.
[0042] Further and preferably, V H The random sequence cassette for the CDR3 sub-library may contain nucleic acid sequences of different lengths. For example, H The random sequence cassette for the -CDR3 sublibrary can be any length of 10 to 30 amino acids, preferably 10 to 25 amino acids, more preferably 10 to 20 amino acids. Thus, as shown in Table 1, H - Oligonucleotides for generating random sequence cassettes for the CDR3 sublibrary may contain various repeats (e.g., 4 to 10 repeats) of "NNK" (representing G / A / T / C, G / A / T / C, G / T) between the sequences encoding D / GR / L and A / G (see also FIG. 3). The generation and diversity of light chain sequences is exemplarily shown in FIG. 4.
[0043] [Table 1]
[0044] [Table 2]
[0045] [Table 3]
[0046] Most typically, the oligonucleotides presented in Tables 1 and 2 are provided in single-stranded DNA, which is converted to a double-stranded DNA fragment using DNA polymerase I (Klenow fragment) to produce a fixed sequenced region (e.g., V L For recombinant nucleic acids such as sub-libraries, the nucleic acids may be inserted into a backbone comprising 5'-(promoter-5'UTR-FW1+CDR1+FW2+CDR2+FW3)-(FW4). Additionally, it is also contemplated that the oligonucleotides presented in Tables 1 and 2 may also be present with complementary oligonucleotides to form double stranded nucleic acids without the use of a polymerase enzyme.
[0047] In some embodiments, the recombinant nucleic acids of the sub-library also contain a nucleic acid sequence encoding a protein tag, so that the peptides encoded by the recombinant nucleic acids can be isolated using a binder for the protein tag. For example, preferred protein tags include the FLAG tag (having the sequence motif DYKDDDDK), the Myc tag (having the sequence motif EQKLISEEDL), and the HA-tag. In some embodiments, the protein tag can be repeated (e.g., three repeats of the FLAG tag (3X FLAG)) to enhance the signal or increase detection.
[0048] It is contemplated that some random sequence cassettes inserted into the recombinant nucleic acids of the sub-library may introduce frameshifts, nonsense mutations, and sequences that destabilize the structure of the peptides encoded by the recombinant nucleic acids. Thus, in some embodiments, we contemplate testing the recombinant nucleic acids of the sub-library in vitro so that any recombinant nucleic acids encoding unstable or misfolded peptides can be removed from the library. For example, V H -CDR3 sublibrary or V L The recombined nucleic acids of the sub-libraries are each independently selected from the V H3 Domain or V L They can be tested for their binding affinity to protein A of Staphylococcus aureus or protein L of Finegoldia magna, which bind to structured epitopes in the (Vκ) domain.
[0049] Any suitable method for screening recombinant nucleic acids by their binding affinity to Protein A or Protein L is contemplated. In an exemplary embodiment, the recombinant nucleic acids of the sub-library are transcribed into mRNA by in vitro transcription, and the 3' end of the mRNA is bound (covalently) to puromycin. Puromycin-bound mRNA is transcribed in vitro, such that peptides transcribed from the puromycin-bound mRNA are bound to the mRNA via puromycin. The peptides are then contacted with Protein A or Protein L to identify peptides that bind efficiently to Protein A or Protein L. Preferably, the peptides are transcribed in a 10-fold sequence. -6 M or less, preferably 10 -7 K below M D Peptides that bind to Protein A or Protein L with an affinity having a V 2 H ... H -CDR3 sublibrary or V L The nucleic acids may be inserted as random sequence cassettes to generate the selected recombinant nucleic acids of the sub-library. Alternatively, it is also contemplated that the recombinant nucleic acids of the sub-library may be in the form of mRNA, optionally pre-bound with a puromycin molecule, so that an in vitro transcription step (in DNA format) for the recombinant nucleic acids may not be required.
[0050] Construction of scFv libraries from sub-libraries The inventors further contemplate that at least two recombinant nucleic acids (members) of the sub-libraries can be recombined to form a recombinant scFv nucleic acid. In a preferred embodiment, each of the at least two recombinant nucleic acids (members) is selected from a different sub-library. For example, one recombinant nucleic acid may be selected from the sub-libraries that contain the V H -CDR1 / 2 sublibraries, multiple V H -CDR3 sublibraries, and V L For another example, one recombinant nucleic acid may be selected from each of the sub-libraries. H -CDR1 / 2 sublibraries, multiple V H -CDR3 sublibraries, and V L A recombinant nucleic acid may be selected from each of two of the sub-libraries. Preferably, at least one of the recombinant nucleic acids selected from the sub-libraries, and more preferably all of them, have been preselected by affinity binding screening as described above.
[0051] Most typically, a recombinant scFv nucleic acid can be constructed by recombining a portion of the recombinant nucleic acid from a sub-library. In this embodiment, the portion of the recombinant nucleic acid comprises a random sequence cassette inserted into the recombinant nucleic acid. Thus, for example, as a first step, V H - a portion of the recombined nucleic acids of the CDR1 / 2 sub-library [ka] (random sequence cassettes are underlined), preferably [ka] More preferably, [ka] Similarly, for example, V H - a portion of the recombined nucleic acids of the CDR3 sub-library [ka] (random sequence cassettes are underlined), preferably [ka] More preferably, [ka] Next, V H -CDR1 / 2 sublibraries and V H - A portion of the recombinant nucleic acids from the CDR3 sub-library are isolated (e.g., by PCR) and recombined (e.g., fused via restriction-ligation methods, generated via recombinant PCR, etc.) to produce V H A domain-recombined nucleic acid can be formed. Thus, typically, V H The domain-modified nucleic acid is [ka] (The random sequence cassette is underlined.) H The domain-recombined nucleic acid may also include a nucleic acid sequence encoding a protein tag (e.g., a FLAG tag, a Myc tag, an HA tag, etc.) at its 3' end as described above. In addition, the V H The domain recombinant nucleic acid is H V as a domain library member H The domains may be arranged in a library.
[0052] The V thus formed H The domain recombinant nucleic acid further comprises a V L The recombinant nucleic acids of the sub-libraries can be recombined to form recombinant scFv nucleic acids. Figure 5 shows one exemplary method for recombining sequences from the sub-libraries. As shown, and typically, V H Part of the domain recombinant nucleic acid and V L A portion of the recombinant nucleic acids of the sub-library is fused to a recombinant scFv nucleic acid. L The recombinant nucleic acids of the sub-library are HThe V domain may be fused to the 3' end of a portion of the recombinant nucleic acid. H A portion of the domain recombinant nucleic acid is [ka] (preferably without any nucleic acid encoding a protein tag at its 3' end), and V L A portion of the recombinant nucleic acids of the sub-library includes [ka] (without the promoter and 5'-UTR). Thus, an exemplary recombinant scFv nucleic acid may include [ka] The structure of V H Part of the domain recombinant nucleic acid and V L It is highly preferred that some of the recombinant nucleic acids of the sub-libraries are positioned in the same reading frame so as to encode a single polypeptide.
[0053] Preferably, V H Part of the domain recombinant nucleic acid and V L Some of the recombinant nucleic acids of the sub-library are fused via a nucleic acid encoding a linker (short peptide spacer fragment) between the two parts. Any suitable length and order of peptide sequences for the linker or spacer may be used. However, it is preferred that the length of the linker peptide is 3-30 amino acids, preferably 5-20 amino acids, more preferably 5-15 amino acids. For example, the inventors have found that glycine-rich sequences (e.g., gly-gly-ser-gly-gly, etc.) are essential for the V H and V L It is contemplated that this will be utilized to provide mobility of the scFv between the domains.
[0054] Optionally, the recombinant scFv nucleic acid may also include a nucleic acid sequence encoding a protein tag (e.g., a FLAG tag, a Myc tag, an HA tag, etc.) at its 3' end as described above. In addition, the recombinant scFv nucleic acid thus produced may be placed in an expression library as an expression library member.
[0055] In some embodiments, the recombinant scFv nucleic acids so formed are further screened and / or classified based on their binding affinity, stability, pH sensitivity, and / or species cross-reactivity to one or more ligands of interest (e.g., cancer antigens, neoepitopes, etc.). For example, the stability of scFv peptides encoded by the recombinant scFv nucleic acids can be analyzed by size exclusion chromatography, which measures the size of the peptide over time. For another example, the pH sensitivity and binding affinity of scFv peptides encoded by the recombinant scFv nucleic acids can be analyzed by contacting the scFv peptides with one or more ligands in different buffer conditions (pH, temperature, etc.).
[0056] With regard to those analyses and further isolation of the desired recombinant scFv nucleic acids from the expression library, the inventors contemplate that the recombinant scFv nucleic acids may be in the form of mRNA, optionally pre-bound with a puromycin molecule at the 3' end of the mRNA. The puromycin-bound mRNA may then be in vitro transcribed, such that the peptides transcribed from the puromycin-bound mRNA are bound to the mRNA via puromycin. The peptides are then contacted with one or more ligands, optionally in different buffer conditions (pH, temperature, etc.). Preferably, the peptides are contacted with one or more ligands at pH 5.0-8.0, preferably pH 6.0-8.0, more preferably pH 6.5-8.0 for 10 min. -6 M or less, preferably 10 -7 K below M DPeptides that bind to the ligand with an affinity having a value of 0.01 to 0.01 are selected and isolated. Once a peptide with high affinity for the ligand is isolated, a cDNA for the isolated peptide can be made via in vitro reverse transcription of puromycin and peptide-bound mRNA.
[0057] Furthermore, the so generated cDNA of the isolated peptide encoded by the recombinant scFv nucleic acid can be grafted and substituted into portions of an immunoglobulin to form a recombinant immunoglobulin or a fragment thereof. For example, the so generated cDNA can be fused to a framework of an immunoglobulin heavy chain constant region such that the variable regions of the immunoglobulin heavy and light chains can be substituted for the scFv formed by the isolated peptide. Alternatively, the inventors have also H Part (or V H Domain derived from recombinant nucleic acid) and V L It is contemplated that portions (or derived from recombinant scFv nucleic acids) can be grafted and substituted onto portions of immunoglobulins to form recombinant immunoglobulins or fragments thereof. For example, the V of a recombinant scFv nucleic acid can be H Part (or V H Domain derived from recombinant nucleic acid) and V L The moiety (or derived from a recombinant scFv nucleic acid) is fused to an immunoglobulin heavy or light chain constant region framework, respectively, to form an immunoglobulin with a variable region specific for the desired ligand.
[0058] In these instances, it is contemplated that immunoglobulins may include any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) and any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) of heavy chain or constant domains that make up the different types of immunoglobulins. In addition, "antibody" may include, but is not limited to, human antibodies, humanized antibodies, chimeric antibodies, monoclonal antibodies, and polyclonal antibodies. In this context, the V antibodies isolated by the contemplated systems and methods are H and V LIt should be noted that grafting domains onto the remainder of an antibody of a desired species (e.g., human) allows for the creation of species-specific antibodies. In another example, the cDNA so generated can be fused to nucleic acids encoding other portions of an immunoglobulin to form immunoglobulin fragments. In this example, it is contemplated that the immunoglobulin fragments can be Fab fragments, Fab' fragments, F(ab')2, disulfide-linked Fvs (sdFvs), and Fvs. The inventors have further demonstrated that portions of the cDNA so generated can be fused to nucleic acids encoding other portions of an immunoglobulin to form VFvs. H Segment and / or V L It is contemplated that any fragment can be formed that comprises any of the segments.
[0059] Furthermore, the inventors contemplate that the scFv portion can be used as a targeting entity for various proteins and non-protein molecules. For example, the scFv portion can be bound to an ALT-803 type molecule (typically as a chimeric protein) to form a TxM entity with specific targeting capabilities (see, for example, J Biol Chem. 2016 Nov 11; 291(46): 23869-23881). In another example, the scFv portion can be bound to a carrier protein (e.g., albumin) to enable target-specific delivery of one or more drugs to a specific location in the tumor microenvironment when the drug is bound to the carrier.
[0060] The inventors further demonstrate that by constructing sub-libraries through targeted diversification of random sequences and / or by pre-selecting the members of the sub-libraries, expression libraries can be expanded to about 10 with minimal loss of diversity by removing unstable, non-binding, or misfolded sequences. 12It is contemplated that the complexity of the expression library can be achieved in a small amount. Thus, the above-described approach to generating an expression library is practical for screening binders / antibodies in small amounts while providing a meaningful order of magnitude in sequence complexity. In addition, the above-described approach to generating an expression library simplifies the binder / antibody screening procedure. Conventionally, in vitro validation of any nucleic acid sequence (e.g., a randomized sequence) encoding a binding domain (or motif) has been performed by filtering the nucleic acid sequence with a F ab The method presented herein involves converting a nucleic acid sequence into an F domain, after which binding affinity can be tested via pull-down assays with a ligand of interest. ab It allows in vitro validation of nucleic acid sequences encoding binding domains (or motifs) through ranking by affinity (e.g., Kd value), pH sensitivity, and species cross-reactivity (e.g., via surface plasmon resonance assays, etc.) without conversion to domains. Furthermore, pre-selection of members from each library based on stability and sensitivity reduces the pool to be tested in the library so that desired binders / scFv / antibody domains can be identified more quickly and efficiently. Therefore, we also used mRNA display technology, where library members after in vitro translation are screened against solid phase-bound antigen, to identify high affinity binders (e.g., nano- and picomolar K) from a high diversity pool. d The present invention contemplates a method for isolating binders having affinity and K on / K off The properties may be further characterized by surface plasmon resonance spectroscopy. Viewed from another perspective, the contemplated systems and methods allow for the rapid detection of binders and the generation of scFvs or antibodies in a process that is completely independent of the in vivo immune system. EXAMPLES
[0061] Working Example Although any suitable diversification scheme can be contemplated to identify the targeted diversification region(s) to maximize diversity while maintaining efficiency, the inventors have found that VH3 / Vk1 may be one of the good candidate regions for randomization among various domains of immunoglobulins, VH3 is considered to be the most stable and soluble VH domain, and Vk1 of the light chain is stable and soluble. Therefore, it is contemplated that the VH3 / Vk1 randomization pair will convert to full-sized immunoglobulin more efficiently. Therefore, the inventors have developed a pre-selection strategy using VH3 and Vk1 frameworks. Figure 1 shows one exemplary randomization strategy using the VH3 / Vk1 pair. The protein sequences of at least 14 immunoglobulin molecules specific to one antigen are compared and analyzed. The most stable and conserved sequence of the 14 immunoglobulin molecules is used as the framework, and the positions of the variable sequences are analyzed to use as the randomized sequence and the degree of randomization (e.g., fully random, partially random, etc.).
[0062] Based on this randomization strategy, we further H Domains CDR1, CDR2-n, CDR2-c (see FIG. 2) and V H For the CDR3 of the domain (see FIG. 3), targeted diversification sequences (randomized sequences, random oligos) were generated. H Domain CDR1, CDR2-n, CDR2-c, CDR3, and V L The process of generating recombinant scFv nucleic acids using random oligos of the CDR3 of the domains is described above and is also shown in the schematic diagram of Figure 4. High diversity libraries were constructed as exemplarily shown in Figure 5 and discussed in more detail above.
[0063] Using the targeted diversification scheme and methods of generating recombinant scFv nucleic acids as described in Figures 1-5, the inventors generated a high diversity library from which recombinant α-B7-H4 801(α-B7-H4, clone number 801) binder was isolated. Recombinant α-B7-H4 801 The stability of α-B7-H4 was determined by analytical size exclusion chromatography for 15 minutes to assess antibody degradation or modification. As shown in FIG. 801 The eluate of α-B7-H4 produced by the above method showed a single peak without any significant smaller peaks. 801 These results indicate that the binders were able to generate scFv or antibodies with high stability.
[0064] The present inventors have developed recombinant α-B7-H4 801 However, it was found that the recombinant α-B7-H4 antibody contains substantially similar antibody components as other commercially available α-B7-H4 antibodies (Rituxan®, LEAF®). 801 and two commercially available α-B7-H4 antibody fragments (Rituxan®, LEAF®) were analyzed via capillary electrophoresis sodium dodecyl sulfate (CE-SDS). As shown in Figure 7, recombinant α-B7-H4 801 CE-SDS separation of the antibody and two commercially available α-B7-H4 antibody (Rituxan®, LEAF®) fragments showed two prominent peaks, corresponding to the light chain (middle peak) and the glycosylated heavy chain (right peak). The left peak indicates the position of the 10 Kd standard marker for CE-SDS analysis.
[0065] The inventors further found that various recombinant α-B7-H4 antibodies can exhibit different binding properties (e.g., affinity, specificity, etc.) to target ligands. Figure 8 shows the binding of two recombinant α-B7-H4 antibodies, α-B7-H4 and α-B7-H4, to B7-H4-expressing 293T cells, as measured by mean fluorescence intensity (MFI). 801 and α-B7-H4 817 The results show that α-B7-H4 801 The antibody, α-B7-H4 817The rightmost panel shows a control experiment with non-specific human IgG1 (hIgG1), which shows that the different randomized CDR domains can confer different binding affinities to the ligand.
[0066] The recombinant α-B7-H4 antibody was further tested to determine specific and efficient binding to the ligand (B7-H4) expressed on antigen presenting cells (APCs) using flow cytometry. As shown in Figure 9, the recombinant α-B7-H4 antibody can specifically bind to the B7-H4 ligand (separating the peak out from non-specific isotype binding), indicating that the recombinant α-B7-H4 antibody is fully functional.
[0067] The present inventors also investigated the effect of B7-H4 (scFv B7-H4 801 ) scFv peptide and scFv B7-H4 801 Recombinant α-B7-H4 antibody (IgG α-B7-H4 801 ) were found to be functionally compatible using a surface plasmon resonance assay. In this assay, Flag-tagged scFv B7-H4 801 is immobilized on the surface via the α-Flag biotinylated antibody that binds to surface-bound neutravidin. Next, the surface-immobilized scFv B7-H4 801 The peptide is contacted with an analyte containing B7-H4. A similar assay was performed with the α-B7-H4 antibody. As shown in FIG. 10 and Table 3, scFv B7-H4 801 and IgG α-B7-H4 801 show substantially similar affinity and binding properties to B7-H4, indicating that they are functionally interchangeable. Furthermore, the binding affinity of in vitro translated peptides (scFv) can be measured directly without grafting the peptide onto an antibody scaffold, allowing efficient screening of many more recombinant scFv nucleic acids in expression libraries.
[0068] [Table 4]
[0069] V H CDR1-3 and V L Among multiple scFv peptides against B7-H4 with various random sequence cassettes in their CDR3, we tested whether the similarity in a particular domain (a particular random sequence cassette) could make the scFv peptides have similar binding properties to the ligand. Five scFv peptides (801, 802, 905, 906, and 817) were tested for their binding affinity to B7-H4. As shown in Table 4, four of them (clones 801, 802, 905, 906) have similar CDR3 sequences. H The four scFv peptides with similar random sequence cassettes in the CDR3 of V showed similar binding affinity to B7-H4 at both 25° C. and 37° C. (as shown in Table 5), which indicates that, at least in the scFv peptides against B7-H4, H These results indicate that sequences in the CDR3 of may be important for binding to a ligand.
[0070] [Table 5]
[0071] [Table 6]
[0072] We also generated multiple scFv peptides that bind to interleukin-8 (IL-8) (scFv IL-8) using the sub-libraries and expression library and tested the affinity to IL-8 in various conditions (temperature and pH). Exemplary scFv IL-8 peptides and their binding affinities measured in various conditions are shown in Table 6. Among the clones shown in Table 6, clones 49-7, 49-1 and 49-12 have similar V H CDR3 sequence, clones 49-19, 49-37, and 49-25 have similar V H In addition, clones 49-3 and 43-2 contain similar V H In contrast to the scFv peptide for B7-H4, we found that the binding affinity of the scFv IL-8 peptide was H We found that the similarity of random sequences in the CDR3 of the clones may not be critically dependent on the similarity of the random sequences in the CDR3 of the clones. For example, clones 49-18, 49-37, and 49-25 have similar V H While containing CDR3 sequences, the binding affinity (K D X10 -9 M) is 0.894X10 -9 M and 25X10 -9 It varies between M.
[0073] [Table 7]
[0074] We further tested whether scFv IL-8 could neutralize the effects of IL-8 by efficiently capturing IL-8 by measuring neutrophil size. Generally, neutrophils are enlarged (e.g., have a larger diameter) when stimulated by IL-8 (as shown in FIG. 11). We verified such IL-8 effects on neutrophil expansion by measuring the size of neutrophils with recombinant α-IL-8 antibody (mAb αIL-8). 201As shown in FIG. 12, the upper left graph) or some scFv IL-8 peptides (αIL-8 #2 , αIL-8 49-3 , αIL-8 49-10 As shown in FIG. 12 , we found that the effect of scFv IL-8 peptide on IL-8 activity was largely abolished by the addition of IL-8 peptide (lower graph), indicating that the scFv IL-8 peptide was able to efficiently neutralize the action of IL-8 by binding to free IL-8 in the culture medium.
[0075] IL-8 is a neutrophil chemotactic factor that induces neutrophils to migrate toward the site of IL-8 release (e.g., the site of infection). To evaluate the functional effect of scFv IL-8 peptide, neutrophils were placed on the bottom of an insert with a porous membrane and placed in a medium containing various concentrations of IL-8 so that neutrophils attracted by IL-8 could transmigrate from the insert through the porous membrane toward the medium. As shown in FIG. 13, increasing the IL-8 concentration in the medium increased the number of migrated neutrophils. Interestingly, such an IL-8 effect was observed in the scFv IL-8 peptide (αIL-8 43-2 ) or recombinant IL-8 antibody derived from scFv IL-8 peptide (mAb αIL-8 201 ) was almost completely eliminated.
[0076] Figure 14 shows further experimental data on various scFvs isolated using the mRNA display library presented herein. More specifically, each data point represents an scFv against the target shown at the bottom, and affinity values for each scFv were determined. As can be seen, the (same) library yielded multiple high affinity binders against a variety of different targets, all with affinity ranges below microM, and many below nanoM. Furthermore, we have also investigated whether the affinity of scFvs can be maintained when CDRs are grafted onto human IgG. Figure 15 shows exemplary results of 29 CDR grafting experiments for selected scFvs grafted onto a human IgG1 scaffold. As can be seen from the results in Figure 15, the humanized IgG1 antibodies retained high specificity and affinity (usually within an order of magnitude).
[0077] Creation of recombinant entities using expression libraries V H Domain Recombinant Nucleic Acids and V LIt is further contemplated that the recombinant scFv nucleic acid formed by recombination of the recombinant nucleic acids of the sub-libraries, or a recombinant nucleic acid encoding one or more antibodies (e.g., IgG, IGM, IgE, IgA, etc.), or fragments thereof, may be further inserted into an expression vector of a recombinant entity (e.g., bacteria, yeast, virus) such that the recombinant scFv fragment may be produced by the recombinant entity or a cell infected with the recombinant entity. Any suitable recombinant entity capable of carrying and / or expressing the recombinant nucleic acid encoding the recombinant scFv fragment is contemplated. For example, the recombinant entity may include any suitable virus, such as adenovirus, adeno-associated virus, alphavirus, herpes virus, lentivirus, etc. However, adenovirus is particularly preferred. It is further preferred that the virus is replication-deficient and non-immunogenic, typically achieved by targeted deletion of selected viral proteins (e.g., E1, E3 proteins). Such desirable properties can be further enhanced by deleting E2b gene function, and as recently reported, high titers of recombinant virus can be achieved using genetically modified human 293 cells (e.g., J Virol. 1998 Feb;72(2):926-933). Therefore, the inventors contemplate that one desirable viral vector may comprise a recombinant adenoviral genome in which the E2b gene has been deleted or is non-functional.
[0078] Alternatively, the recombinant entity may be a bacterium and the expression vector may be expressed in a genetically engineered bacterium that expresses endotoxin at such a low level that it does not cause an endotoxic response in human cells and / or may be a bacterial vector that may be insufficient to induce CD14-mediated sepsis when introduced into the human body. An example of a bacterial strain with modified lipopolysaccharide is ClearColi® BL21(DE3) electrocompetent cells. This bacterial strain is BL21 with the genotype F-ompT hsdSB(rB-mB-)gal dcm lon λ(DE3[lacI lacUV5-T7 gene1 ind1 sam7 nin5])msbA148 ΔgutQΔkdsD ΔlpxLΔlpxMΔpagPΔlpxPΔeptA. In this context, several specific deletion mutations (ΔgutQ ΔkdsD ΔlpxL ΔlpxMΔpagPΔlpxPΔeptA) have been shown to mediate the expression of lipid IV of LPS. A It should be understood that the LPS precursor IVA encodes a modification to the LPS precursor IVA, but one additional compensatory mutation (msbA148) allows cells to maintain survival in the presence of the LPS precursor lipid IVA. These mutations result in the deletion of oligosaccharide chains from LPS. More specifically, two of the six acyl chains are deleted. The six acyl chains of LPS are the trigger recognized by Toll-like receptor 4 (TLR4) in complex with myeloid differentiation factor 2 (MD-2), leading to the activation of NF-κB and the production of inflammatory cytokines. Lipid VI, which contains only four acyl chains A is not recognized by TLR4 and therefore does not trigger an endotoxic response. Although electrocompetent BL21 bacteria are described as an example, the inventors contemplate that the genetically modified bacteria can also be chemically competent bacteria. Alternatively or additionally, the recombinant entity can be a yeast and the expression vector can also be a yeast vector that can be expressed in yeast, preferably Saccharomyces cerevisiae (e.g., GI-400 series recombinant immunotherapy yeast strains, etc.).
[0079] We may use multiple recombinant scFv nucleic acids and / or recombinant nucleic acids encoding one or more antibodies (e.g., IgG, IgM, IgE, IgA, etc.) to generate a set of recombinant entities (e.g., recombinant viruses) to increase the diversity of therapeutically effective recombinant entities. Preferably, multiple recombinant scFvs and / or nucleic acids encoding one or more antibodies (e.g., IgG, IgM, IgE, IgA, etc.) may be selected based on the affinity and / or binding properties (e.g., binding kinetics, etc.) of the scFv fragments or antibodies to the antigen, such that the top 30%, top 20%, top 10%, or up to 5% of scFv fragments or antibodies with the highest binding affinity or other binding properties may be selected from a pool of scFv fragments or antibodies. In some embodiments, such a selection process may include the selection and enrichment of high-pass fragments through multiple rounds of selection. For example, in some embodiments, the top 30% of scFv fragments or antibodies with the highest binding affinities may be selected in a first round of selection, the top 50% of the top 30% scFv fragments or antibodies (from the first round) with highest binding affinities may be selected in a second round of selection, etc. While any suitable number of rounds of selection and pass-through rate (e.g., top 30%, top 20%, etc.) may be used, it is preferred that the final set of scFv fragments or antibodies may constitute the top 30%, top 20%, top 10%, or up to 5% of the scFv fragments with highest binding affinities in the entire pool of scFv fragments or antibodies.
[0080] The recombinant scFv nucleic acids thus obtained, and / or sets of recombinant nucleic acids encoding one or more antibodies (e.g., IgG, IgM, IgE, IgA, etc.) may be further used to generate a heterogeneous pool of recombinant entities (e.g., recombinant viruses) that may further generate multiple different scFv fragments and / or antibodies that bind to the same antigen. Without wishing to be bound by any particular theory, the inventors anticipate that such an approach may increase the chances of identifying scFv fragments and / or antibodies that may most effectively bind to the antigen by increasing the pool of high affinity candidate scFv fragments. In other words, the recombinant scFv fragment or antibody with the highest binding affinity may not be the most therapeutically effective scFv fragment or antibody due to many variables in vivo (e.g., slight individual structural differences in antigens between patients, different binding conditions (e.g., pH, other environmental hazards, etc.), etc.), or because the recombinant scFv fragment or antibody with the highest binding affinity may have undesirable kinetic properties as a therapeutic antibody. Therefore, by generating a heterogeneous pool of recombinant entities using a set of nucleic acids encoding various scFv fragments or antibodies, there is an opportunity to identify therapeutically effective scFv fragments (even if they do not have the highest binding affinity to the antigen). In addition, a heterogeneous pool of antibodies (generated from a heterogeneous pool of recombinant entities) that bind to the same antigen may increase the effectiveness for targeting the antigen in vivo compared to a homogeneous pool of antibodies that may simultaneously lose effectiveness under certain in vivo conditions. In other words, the inventors expect that a heterogeneous pool of recombinant entities (especially recombinant viruses carrying recombinant nucleic acids encoding various scFv fragments or antibodies targeting the same antigen) may be more therapeutically beneficial and / or effective in treating patients with tumors.
[0081] In some embodiments, the expression vector may include a nucleic acid segment encoding a signaling peptide for extracellular secretion such that the produced recombinant scFv or antibody may be secreted from the cell. While any suitable signaling peptide is contemplated, an exemplary signaling peptide may include 5-30 amino acids with a positively charged N-terminal region (n-region), a hydrophobic central region (h-region), and a neutral polar C-terminal region (c-region), which may be cleaved during intracellular transport. The nucleic acid segment encoding the signaling peptide may preferably be located at the N-terminus of the recombinant nucleic acid encoding the scFv (optionally via a shorter linker, e.g., a nucleic acid encoding a glycine-rich linker).
[0082] Alternatively and / or in addition, the expression vector may further comprise one or more elements capable of inducing or increasing an immune response against the tumor and / or increasing the activity of the generated scFv fragment. Thus, in some embodiments, the expression vector may comprise another nucleic acid segment encoding a neo-antigen, a tumor-associated antigen, or a tumor-specific, patient-specific neo-epitope, a costimulatory molecule, an immunostimulatory cytokine, a recombinant immunoglobulin protein complex, and / or a checkpoint inhibitor. With regard to this cytokine, any suitable cytokine capable of modulating the immune response (e.g., increasing or decreasing T cell activity, etc.) is contemplated. Thus, contemplated costimulatory molecules may include B7.1 (CD80), B7.2 (CD86), CD30L, CD40, CD40L, CD48, CD70, CD112, CD155, ICOS-L, 4-1BB, GITR-L, LIGHT, TIM3, TIM4, ICAM-1, LFA3 (CD58), and members of the SLAM family. In addition, the cytokine may be IL-15 superagonist (IL-15N72D) and / or IL-15 superagonist / IL-15RαSushi-Fc fusion complex (e.g., ALT-803) bound to at least one of IL-7, IL-15, IL-18, IL-21, and IL-22, or preferably bound to both IL-7 and IL-21. Contemplated costimulatory molecules may include B7.1 (CD80), B7.2 (CD86), CD30L, CD40, CD40L, CD48, CD70, CD112, CD155, ICOS-L, 4-1BB, GITR-L, LIGHT, TIM3, TIM4, ICAM-1, LFA3 (CD58), and members of the SLAM family. Exemplary checkpoint inhibitors include CTLA-4 (particularly CD8 + cells), PD-1 (especially CD4 + For cells, antibodies or binding molecules against the TIM1 receptor, 2B4, and CD160, such as ipilimumab and nivolumab.
[0083] In some embodiments, recombinant entities may be used to generate scFv fragments and / or antibodies in vitro. For example, recombinant bacteria or yeast may be induced and / or cultured to express scFv proteins, and the scFv fragment proteins so expressed may be further purified and / or isolated by any suitable method (e.g., affinity binding purification, etc.) for further use. In other embodiments, recombinant entities may be used to infect mammalian cells in vivo and / or ex vivo. For example, a recombinant virus carrying a recombinant nucleic acid encoding an scFv fragment may infect mammalian cells in vitro (or ex vivo) by co-incubating the recombinant virus with mammalian cells to produce the scFv fragment in the mammalian cells. In such examples, the mammalian cell may be any suitable mammalian cell capable of producing a protein from an exogenous nucleic acid that secretes a recombinant scFv fragment, including any established cell line (human or non-human, e.g., HEK-293 cells, CHO cells, etc.), or an autologous cell obtained from a patient with a tumor (e.g., autologous B cells isolated and / or expanded ex vivo, etc.).
[0084] Alternatively, a recombinant virus carrying recombinant nucleic acid encoding the scFc fragment and / or antibody may be administered to a human or mammal (bearing a tumor) so that the scFc fragment and / or antibody may be produced and secreted in vivo. In such an embodiment, the recombinant virus may be formulated in any pharma- ceutically acceptable carrier, preferably with a viral titer of 10 or more per dosage unit. 4 ~10 12The recombinant virus formulation may be formulated as a sterile injectable composition, each of which is a single viral particle. However, alternative formulations are contemplated herein as suitable for use, and all known routes and modes of administration are contemplated herein. As used herein, the term "administering" a recombinant virus formulation refers to both direct and indirect administration of the recombinant virus formulation, with direct administration of the recombinant virus formulation typically being performed by a medical professional (e.g., a doctor, a nurse, etc.) and indirect administration including providing or making available the recombinant virus formulation to a medical professional for direct administration (e.g., by injection, infusion, oral delivery, topical delivery, etc.).
[0085] In some embodiments, the recombinant virus formulations are administered by systemic injection, such as subcutaneous, subdermal, or intravenous injection. In other embodiments, where systemic injection may not be efficient (such as in the case of brain tumors), it is contemplated that the recombinant virus formulations are administered by intratumoral injection.
[0086] With regard to the dose and schedule of administration of the recombinant virus formulation, it is contemplated that the dose and / or schedule may vary depending on the type, size, location of the tumor, the health status of the patient (including, for example, age, sex, etc.), and any other relevant conditions. Although variable, the dose and schedule may be selected and adjusted so that the recombinant virus does not have any significant toxic effect on normal cells of the host, yet is sufficient to be effective in inducing the production of recombinant scFv fragments to treat the tumor in such a way. For example, contemplated doses of the recombinant virus formulation may be at least 10 6 virus particles / day, or at least 10 8 virus particles / day, or at least 10 10 virus particles / day, or at least 10 11virus particles / day. In some embodiments, a single dose of the recombinant virus preparation may be administered at least once a day or twice a day (half a dose per administration) for at least one day, at least three days, at least one week, at least two weeks, at least one month, or any other desired schedule. In other embodiments, the dose of the recombinant virus preparation may be gradually increased during the schedule or gradually decreased during the schedule. In still other embodiments, several series of administrations of the recombinant virus preparation may be separated by intervals (e.g., one administration each for three consecutive days, and one administration each for three more consecutive days spaced apart by seven days, etc.).
[0087] It should be apparent to one skilled in the art that many more variations than those already described are possible without departing from the inventive concept herein. Accordingly, the subject matter of the present invention is not limited except as set forth in the appended claims. Moreover, in interpreting both this specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprise" and "comprising" should be interpreted as referring to an element, component, or step in a non-exclusive manner, indicating that the referenced element, component, or step may be present, utilized, or combined with other elements, components, or steps not expressly referenced. As used throughout this specification and the claims that follow, the meanings of "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Also, as used herein, the meaning of "in" includes "in" and "on," unless the context clearly dictates otherwise. Where a claim herein refers to at least one selected from the group consisting of A, B, C, .... and N, the text should be construed to require only one element from the group, and not A+N, or B+N, etc.
Claims
1. A recombinant virus comprising: recombinant nucleic acids comprising members of an expression library encoding distinct antibodies or antibody fragments; The members of the expression library include (1) V H -CDR1 / 2 sublibrary, (2) a plurality of V H -CDR3 sublibrary, and (3) V L generating or providing sub-libraries, each of said sub-libraries (1)-(3) comprising a plurality of members; creating or providing, each member of said sub-library comprising at least one random cassette having a plurality of degenerate base positions; The V H - CDR1 / 2 sub-libraries, said plurality of V H -CDR3 sublibraries, and L recombining at least a portion of at least two members of a sub-library to form said expression library member in said expression library. A recombinant virus produced by
2. The recombinant virus of claim 1, which is a genetically modified, low immunogenic virus.
3. 3. The recombinant virus of claim 2, which is a human adenovirus serotype 5 having a mutation in at least one of the following genes: E1A, E1B, E2B, E3.
4. The V H - the plurality of members of the CDR1 / 2 sub-library are H A portion of CDR1 and V H The recombinant virus of any one of claims 1 to 3, comprising a random cassette corresponding to at least one portion of CDR2.
5. The V H - multiple members of the CDR1 / 2 sublibrary are V H At least a portion of CDR1 and V H The recombinant virus of any one of claims 1 to 4, comprising a plurality of random cassettes corresponding to a portion of CDR2.
6. The V H - multiple members of the CDR1 / 2 sublibrary are V H The recombinant virus of claim 4, comprising a plurality of random cassettes corresponding to at least a portion of CDR2.
7. The V H - multiple members of the CDR3 sublibrary are V H The recombinant virus of any one of claims 1 to 6, comprising a random cassette corresponding to at least a portion of CDR3.
8. The V H The recombinant virus according to any one of claims 1 to 7, wherein at least two random cassettes of the members of the -CDR3 sublibrary encode peptides of different lengths.
9. The recombinant virus of claim 8, wherein the peptide has a length in the range of 10 to 20 amino acids.
10. The recombinant virus of any one of claims 1 to 9, wherein the members of the sub-library share a common sequence.
11. The V L The plurality of members of the sub-library are L The recombinant virus according to any one of claims 1 to 10, comprising a random cassette in a portion of CDR3.
12. The recombination step comprises H - at least a portion of said members of a CDR1 / 2 sub-library and said plurality of V H -CDR3 sublibraries and fused together to produce V H V in the domain library H forming a domain library member, H The domain library consists of multiple V H The method of any one of claims 1 to 11, further comprising forming a recombinant virus comprising a domain library member.
13. The members of the expression library are L isolating at least a portion of the members of the sub-library; L A portion of the members of the sub-library and the V H 13. The recombinant virus of claim 12, which has been produced by fusing one of the domain library members to form the expression library member.
14. The recombination step comprises H - at least a portion of said members of a CDR1 / 2 sub-library and said plurality of V H - one of the CDR3 sub-libraries and fusing them together to form a first group of expression library members.
15. The recombinant virus of any one of claims 1 to 14, wherein the recombinant nucleic acid further comprises a nucleic acid fragment encoding a signaling peptide that facilitates secretion of the distinct antibody or antibody fragment.
16. The recombinant virus of any one of claims 1 to 15, wherein the distinct antibody or antibody fragment comprises an scFv.
17. The recombinant virus of claim 17, further comprising a step of subcloning the expression library members to construct an IgG1 carrying the scFv.
18. The recombinant virus of any one of claims 1 to 17, wherein the random cassette is generated using an oligonucleotide selected from SEQ ID NO: 1 to SEQ ID NO:
25.
19. (1) V H -CDR1 / 2 sublibrary, (2) a plurality of V H -CDR3 sublibrary, and (3) V L generating or providing sub-libraries, each of said sub-libraries (1)-(3) comprising a plurality of members; each member of said sub-library comprising at least one random cassette having a plurality of degenerate base positions; The V H -CDR1 / 2 sub-libraries, said plurality of VH-CDR3 sub-libraries, and said V L recombining at least a portion of at least two members of the sub-libraries to form an expression library member in an expression library, said expression library comprising a plurality of expression library members, each expression library member encoding a distinct antibody or antibody fragment; and Producing a recombinant viral vector comprising at least one expression library member. A method for producing a recombinant antibody comprising the steps of:
20. 20. The method of claim 19, wherein the recombinant viral vector is derived from a genetically modified, low immunogenic virus.
21. 21. The method of claim 20, wherein the genetically modified, low immunogenic virus is a human adenovirus serotype 5 having a mutation in at least one of the following genes: E1A, E1B, E2B, E3.
22. The V H - multiple members of the CDR1 / 2 sublibrary are V H A portion of CDR1 and V H The method of any one of claims 19 to 21, comprising a random cassette corresponding to at least one of the portions of CDR2.
23. The V H - multiple members of the CDR1 / 2 sublibrary are V H At least a portion of CDR1 and V H The method of any one of claims 19 to 21, comprising a plurality of random cassettes corresponding to portions of CDR2.
24. The V H - multiple members of the CDR1 / 2 sublibrary are V H 24. The method of claim 23, comprising a plurality of random cassettes corresponding to at least a portion of CDR2.
25. The V H - multiple members of the CDR3 sublibrary are V H The method of any one of claims 19 to 24, comprising a random cassette corresponding to at least a portion of CDR3.
26. The V H The method according to any one of claims 19 to 25, wherein at least two random cassettes of the members of the CDR3 sublibrary encode peptides having different lengths.
27. 27. The method of claim 26, wherein the peptide has a length in the range of 10 to 20 amino acids.
28. The V L The plurality of members of the sub-library are L The method according to any one of claims 19 to 27, comprising a random cassette in a portion of CDR3.
29. The method of any one of claims 19 to 28, wherein the members of the sub-library share a common sequence.
30. The method of any one of claims 19 to 29, wherein each of the expression library members comprises a plurality of the random cassettes.
31. The recombination step comprises H - at least a portion of the members of the CDR1 / 2 sublibrary and said plurality of V H -CDR3 sublibraries were isolated and fused together to form V H V in the domain library H forming a domain library member, H The domain library consists of multiple V H The method of any one of claims 19 to 30, comprising a domain library member.
32. The V L isolating at least a portion of the members of the sub-library; L Some of the members of the sub-library are H 32. The method of claim 31, further comprising fusing with one of a domain library to form the expression library member.
33. The V L 33. The method of claim 32, wherein some of the members of the sub-library are linked via a sequence encoding a linker.
34. 34. The method of claim 33, wherein the linker is a glycine-rich peptide.
35. The recombination step comprises H - at least a portion of the members of the CDR1 / 2 sublibrary and said plurality of V H - isolating one of the CDR3 sub-libraries and fusing them together to form the first group of expression library members.
36. a second group of expression library members, said second group comprising said V L 36. The method of claim 35, further comprising the second group comprising at least a portion of the members of the sub-library.
37. The method of any one of claims 19 to 36, wherein the distinct antibody or antibody fragment comprises an scFv.
38. 38. The method of claim 37, further comprising subcloning the expression library members to construct an IgG1 carrying the scFv.
39. Subcloning one member each from each of the first and second groups to produce recombinant V H and V L 37. The method of claim 36, further comprising forming an IgG1 having the domain.
40. 40. The method of any one of claims 19 to 39, further comprising selecting a subset of said expression library members based on at least one of the following: affinity for a ligand, pH sensitivity, and species cross-reactivity.
41. 41. The method of claim 40, further comprising selecting a subset of said expression library members that encode scFv that bind to said ligand with a Kd of less than 50 nM.
42. The method of any one of claims 19 to 41, wherein the random cassette is generated using oligonucleotides selected from SEQ ID NO: 1 to SEQ ID NO:
25.
43. transcribing the expression library members into mRNA fragments; and attaching a puromycin molecule at the 3' end of said mRNA fragment. The method of any one of claims 19 to 42, further comprising:
44. The method according to any one of claims 19 to 43, further comprising the step of contacting a recombinant virus carrying the recombinant viral vector with a mammalian cell.
45. 45. The method of any one of claims 19 to 44, wherein the contacting step comprises administering the recombinant virus to a mammal.
46. 46. The method of any one of claims 1 to 45, wherein the mammalian cells are autologous cells of a tumor-bearing patient, and the contacting step comprises co-incubating the autologous cells and the mammalian cells ex vivo.
47. Use of a composition according to any one of claims 1 to 18 for generating therapeutic recombinant antibodies against cancer neoepitopes.
48. 1. A method for isolating high affinity binders having an affinity of 100 nM or less for an antigen, comprising the steps of: A method comprising the step of contacting said antigen with a composition constructed by the method of any one of claims 19 to 46.
Citation Information
Patent Citations
Universal antibody library
JP2008536473A
mRNA display antibody library and method
JP2021503292A
Cell display of antibody libraries
US20070111260A1
